Mitchell A. Bekritsky

Mitchell A. Bekritsky

Auto-generated profile, based on publicly available information

Mitchell A. Bekritsky

Illumina Limited, Chesterford Research Park, Little Chesterford, Nr Saffron Walden, Essex, CB10 1XL, United Kingdom

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2018 in Nature Methods
Verified
Journal Article
Closed access
PDF file
SKSangtae Kim
Sangtae Kim
KSKonrad Scheffler
Konrad Scheffler
AHAaron L. Halpern
Aaron L. Halpern
MBMitchell A. Bekritsky
Mitchell A. Bekritsky
ENEunho Noh
Eunho Noh
CSChristopher T. Saunders
Christopher T. Saunders

1 April 2012 in Neuron
Verified
Journal Article
Closed access
IIIvan Iossifov
Ivan Iossifov
MRMichael Ronemus
Michael Ronemus
DLDan Levy
Dan Levy
ZWZihua Wang
Zihua Wang
IHInessa Hakker
Inessa Hakker
MWMichael Wigler
Michael Wigler

8 September 2017 in Genome Research
Verified
Journal Article
Open access
PDF file
EDEgor Dolzhenko
Egor Dolzhenko
JVJoke J.F.A. van Vugt
Joke J.F.A. van Vugt
RSRichard J. Shaw
Richard J. Shaw
MBMitchell A. Bekritsky
Mitchell A. Bekritsky
MBMarka van Blitterswijk
Marka van Blitterswijk
MEMichael A. Eberle
Michael A. Eberle
Identifying large expansions of short tandem repeats (STRs), such as those that cause amyotrophic lateral sclerosis (ALS) and fragile X syndrome, is challenging for short-read whole-genome sequencing (WGS) data. A solution to this problem is an important step toward integrating WGS into precision medicine. We developed a software tool called ExpansionHunter that, using PCR-free WGS short-read data, can genotype repeats at the locus of interest, even if the expanded repeat is larger than the read length. We applied our algorithm to WGS data from 3001 ALS patients who have been tested for the presence of the C9orf72 repeat expansion with repeat-primed PCR (RP-PCR). Compared against this truth data, ExpansionHunter correctly classified all (212/212, 95% CI [0.98, 1.00]) of the expanded samples as either expansions (208) or potential expansions (4). Additionally, 99.9% (2786/2789, 95% CI [0.997, 1.00]) of the wild-type samples were correctly classified as wild type by this method with the remaining three samples identified as possible expansions. We further applied our algorithm to a set of 152 samples in which every sample had one of eight different pathogenic repeat expansions, including those associated with fragile X syndrome, Friedreich's ataxia, and Huntington's disease, and correctly flagged all but one of the known repeat expansions. Thus, ExpansionHunter can be used to accurately detect known pathogenic repeat expansions and provides researchers with a tool that can be used to identify new pathogenic repeat expansions.

30 November 2016 in Genome Research
Verified
Journal Article
Open access
PDF file
MEMichael A. Eberle
Michael A. Eberle
EFEpameinondas Fritzilas
Epameinondas Fritzilas
PKPeter Krusche
Peter Krusche
MKMorten Källberg
Morten Källberg
BMBenjamin L. Moore
Benjamin L. Moore
DBDavid R. Bentley
David R. Bentley
Improvement of variant calling in next-generation sequence data requires a comprehensive, genome-wide catalog of high-confidence variants called in a set of genomes for use as a benchmark. We generated deep, whole-genome sequence data of 17 individuals in a three-generation pedigree and called variants in each genome using a range of currently available algorithms. We used haplotype transmission information to create a phased “Platinum” variant catalog of 4.7 million single-nucleotide variants (SNVs) plus 0.7 million small (1–50 bp) insertions and deletions (indels) that are consistent with the pattern of inheritance in the parents and 11 children of this pedigree. Platinum genotypes are highly concordant with the current catalog of the National Institute of Standards and Technology for both SNVs (>99.99%) and indels (99.92%) and add a validated truth catalog that has 26% more SNVs and 45% more indels. Analysis of 334,652 SNVs that were consistent between informatics pipelines yet inconsistent with haplotype transmission (“nonplatinum”) revealed that the majority of these variants are de novo and cell-line mutations or reside within previously unidentified duplications and deletions. The reference materials from this study are a resource for objective assessment of the accuracy of variant calls throughout genomes.

17 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SCSiyuan Cheng
Siyuan Cheng
QZQing Zhang
Qing Zhang
XZXinchang Zheng
Xinchang Zheng
SJShalini Jhangiani
Shalini Jhangiani
JWJacqueline C Weir
Jacqueline C Weir
FSFritz Sedlazeck
Fritz Sedlazeck
Despite significant advances in genomic sequencing, the resolution of many rare disease cases is still hindered by variant detection limitations. Short reads struggle in homologous regions, and long reads remain costly and difficult to scale. Here, we present the first systematic evaluation of Illumina’s Constellation sequencing technology for rare disease research. By fragmenting long DNA molecules directly on the flow cell surface, Constellation unlocks proximity information that enables long-range phasing and structural variant detection. Across 21 families, Constellation independently identified all known causative variants and resolved previously unsolved trios. It reliably resolved complex structural and copy number variants (e.g. impacting MECP2 ) and recovered haplotype phasing information across key disease impacting variants, all from low DNA input using existing Illumina infrastructure. These findings establish Constellation as a scalable, cost-efficient advance, closing critical diagnostic gaps and broadening access to long-range variant analysis in rare disease genomics.